Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China

Abstract

Purpose: This study aimed to compare the clinical outcomes of camrelizumab in hepatitis B virus-related hepatocellular carcinoma (HBV–HCC) patients and non-HBV, non-HCV hepatocellular carcinoma (NBNC–HCC) patients in China.Materials and methods: A total of 54 patients with hepatocellular carcinoma who received camrelizumab were included in this retrospective study from January 2019 to December 2021. The patients were assigned to the HBV–HCC group (n = 28) and the NBNC–HCC group (n = 26). The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoints were the objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Multivariate analysis using Cox proportional hazard regression was used to identify independent prognostic factors. A nomogram model was subsequently established based on independent prognostic factors.Results: The mean duration of follow-up was 12.7 ± 3.6 months. The median OS was not determined. The median PFS in the HBV–HCC group was significantly longer than that in the NBNC–HCC group (9.2 vs. 6.7 months, p = 0.003). The ORR and DCR in the HBV–HCC group were significantly higher than those in the NBNC–HCC group (ORR, 28.6% vs. 7.7%, p = 0.048; DCR, 71.4% vs. 42.3%, p = 0.031). No significant differences in the total incidence of AEs were found between the HBV–HCC group and the NBNC–HCC group (75.0% vs. 69.2%, p = 0.224). Multivariate regression analysis identified etiology, AFP level, and vascular invasion as independent prognostic factors (all p < 0.05).Conclusion: Our findings demonstrate that camrelizumab is more effective in HBV–HCC patients than in NBNC–HCC patients, with manageable safety.

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis

“…Fourteen studies included DCR parameters [ 4 , 6 – 8 , 12 – 14 , 16 , 20 – 23 , 26 , 27 ]. The pooled DCR of uninfected patients and HCV and HBV patients was 58.74% (95% CI: 46.89%–70.13%), 67.83% (95% CI: 52.01%–82.14%), and 65.79% (95% CI: 58.86%–72.43%).…”

“…Median overall survival (mOS) was published by 12 studies [ 8 – 12 , 15 , 17 , 19 , 20 , 22 , 23 , 27 ]. According to the meta-analysis, the pooled mOS was 13.30 months (95% CI: 8.24–18.36), 18.29 months (95% CI: −0.61–37.18), 12.90 months (95% CI: 9.85–15.96), and 15.44 months (95% CI: 8.86–22.01) for patients who were uninfected and those who had HCV, HBV, and hepatitis ( Figure 5 ).…”

“…The incidence of immune-related adverse events (irAEs) in hepatitis patients and uninfected patients was further combined. A total of 13 studies reported irAEs [ 4 , 7 , 8 , 10 – 12 , 14 , 16 , 18 – 20 , 22 , 27 ]. irAEs were classified into all grades and grades 3-4.…”

“…Median progression-free survival (mPFS) was published by 11 studies [8,9,12,15,17,19,20,[22][23][24]27]. Te pooled mPFS (Figure 4) was 5.01 months (95% CI: 4.05-5.97) for uninfected patients, 5.72 months (95% CI: 2.29-9.15) for patients with HCV, and 4.39 months (95% CI: 2.12-6.66) for patients with HBV.…”

A comment on hemihepatic versus total hepatic inflow occlusion for laparoscopic hepatectomy: a randomized controlled trial

“…The background characteristics of patients showed that more than half of the patients were diagnosed with hepatocellular carcinoma (HCC) in both groups in Table 1 . In China, HCC caused by hepatitis B virus (HBV) comprises ~70–80%, and HBV-related HCC is associated with worsened liver function 2 . In addition, liver resection in patients suffering from HBV-related cirrhosis is challenging as a result of portal pressure and impaired coagulation function.…”